超益生菌血症和勃罗莫克里治疗对大脑血流和大脑功能状态的影响
Manxi Xu1,2, Bing Liu1, Aocai Yang1
1Department of Radiology, China-Japan Friendship Hospital, No.2 Yinghua East Road, Chaoyang District, Beijing 100029, China, beijing, China.
Neuroradiology
|July 19, 2025
概括
超益生菌血症 (HPRL) 降低了脑血流 (CBF) 并破坏了大脑网络组织. 勃罗莫克里普丁治疗可能有助于恢复CBF,提供对神经生理学影响的见解.
科学领域:
- 神经科学是一个神经科学.
- 放射学 放射学是一门学科.
- 内分泌学 在内分泌学.
背景情况:
- 超益生菌血症 (HPRL) 影响生殖和中枢神经系统功能.
- 对于HPRL对大脑功能和脑血流 (CBF) 的具体影响尚不完全理解.
研究的目的:
- 研究HPRL对大脑血流 (CBF) 和功能性大脑网络的影响.
- 在HPRL患者中检查烯治疗对这些参数的影响.
主要方法:
- 使用了多模式磁共振成像 (MRI).
- 分析了32名HPRL患者 (一些人服用布罗莫克里) 和40名健康对照.
- 评估了大脑血流 (CBF) 和功能网络特征.
主要成果:
- 在HPRL患者中,全球平均CBF显著降低,特别是在特定的大脑区域.
- 在HPRL患者中,右中额头回表现出增加的CBF.
- 勃罗莫克里丁治疗与全球CBF的上升趋势相关.
- 在HPRL患者中观察到功能网络的层次结构下降,与益乳素水平负相关.
- 默认模式和传感器电机网络之间的连接性可能会减少.
结论:
- HPRL显著改变CBF和功能性大脑网络组织.
- 勃罗莫克里丁治疗显示出恢复CBF的潜力.
- 这些发现增强了对HPRL对大脑影响的基础神经生理机制的理解.
更多相关视频
07:14A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
14.9K
09:36In vivo Positron Emission Tomography to Reveal Activity Patterns Induced by Deep Brain Stimulation in Rats
Published on: March 23, 2022
2.3K
相关概念视频
Parkinson's Disease: Treatment
381
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
381
The Blood-brain Barrier
48.8K
Overview
48.8K
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Brain Imaging
317
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
317
Parkinson's Disease: Overview
713
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
713
Attention-Deficit/Hyperactivity Disorder
294
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
294
